CoChat

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

Fathi, Amir T., Sadrzadeh, Hossein, Borger, Darrell R., Ballen, Karen K., Amrein, Philip C., Attar, Eyal C., Foster, Julia, Burke, Meghan, Lopez, Hector U., Matulis, Christina R., Edmonds, Katherine M., Iafrate, A. John, Straley, Kimberly S., Yen, Katharine E., Agresta, Samuel, Schenkein, David P., Hill, Cedric, Emadi, Ashkan, Neuberg, Donna S., Stone, Richard M., Chen, Yi-Bin · 2012 · Blood
Cited by 123

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recently described in acute myeloid leukemia (AML). Serum and myeloblast samples from patients with IDH-mutant AML contain high levels of the metabolite 2-hydroxyglutarate (2-HG), a product of the altered IDH protein. In this prospective study, we sought to determine whether 2-HG can potentially serve as a noninvasive biomarker of disease burden through serial measurements in patients receiving conventional therapy for newly diagnosed AML. Our data demonstrate that serum, urine, marrow aspirate, and myeloblast 2-HG levels are significantly higher in IDH-mutant patients, with a correlation between baseline serum and urine 2-HG levels. Serum and urine 2-HG, along with IDH1/2-mutant allele burden in marrow, decreased with response to treatment. 2-HG decrease was more rapid with induction chemotherapy compared with DNA-methyltransferase inhibitor therapy. Our data suggest that serum or urine 2-HG may serve as noninvasive biomarkers of disease activity for IDH-mutant AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-06-438267

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 123

Metadata

Authors
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M., Lopez, H. U., Matulis, C. R., Edmonds, K. M., Iafrate, A. J., Straley, K. S., Yen, K. E., Agresta, S., Schenkein, D. P., Hill, C., Emadi, A., Neuberg, D. S., Stone, R. M., & Chen, Y.-B.
Venue
Blood
Published
2012-11-29
Volume
120
Issue
23
Pages
4649-4652
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2047322423
Cited by
123
References
11
FWCI
8.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. https://app.cochat.ai/papers/10.1182/blood-2012-06-438267
The paper
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M., Lopez, H. U., Matulis, C. R., Edmonds, K. M., Iafrate, A. J., Straley, K. S., Yen, K. E., Agresta, S., Schenkein, D. P., Hill, C., Emadi, A., Neuberg, D. S., . . . Chen, Y.-B. (2012). Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. https://doi.org/10.1182/blood-2012-06-438267

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.